Asked by: Paul Davies (Labour - Colne Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what specific actions the Department is taking, in response to the Chief Medical Officer’s report on the health of people in prison, published on 6 November 2025, to improve access to effective drug treatment and support services across the criminal justice pathway, including upon release from custody.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We welcome the Chief Medical Officer’s report on the health of people in prison, on probation and in the secure National Health Service estate in England and we are carefully considering the findings and recommendations.
The Department is committed to working with partners to reduce health inequalities for prisoners and is a signatory of the National Partnership Agreement which supports commissioning and delivery of appropriate service in prisons. We recognise that there is more we need to do to address health issues for this cohort. In addition, NHS England is updating all 19 health and justice service specifications by March 2026, which should provide opportunities to improve healthcare in prisons.
With specific regard to improving access to effective drug treatment and support services across the criminal justice pathway, including upon release from custody, the Department works closely with national partners and with local authorities to improve continuity of care between prison and community drug and alcohol treatment systems. To support this the Department has published a continuity of care self-assessment toolkit and shares actionable data and good practice with drug and alcohol partnerships on a regular basis. The toolkit is available at the following link:
Asked by: Paul Davies (Labour - Colne Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the Department’s timelines are for implementing the recommendations set out in the Chief Medical Officer’s report, Health of People in Prison, on Probation and in the Secure NHS Estate in England, published on 6 November 2025.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We welcome the Chief Medical Officer’s report on the health of people in prison, on probation and in the secure National Health Service estate in England and we are carefully considering the findings and recommendations.
The Department is committed to working with partners to reduce health inequalities for prisoners and is a signatory of the National Partnership Agreement which supports commissioning and delivery of appropriate service in prisons. We recognise that there is more we need to do to address health issues for this cohort. In addition, NHS England is updating all 19 health and justice service specifications by March 2026, which should provide opportunities to improve healthcare in prisons.
With specific regard to improving access to effective drug treatment and support services across the criminal justice pathway, including upon release from custody, the Department works closely with national partners and with local authorities to improve continuity of care between prison and community drug and alcohol treatment systems. To support this the Department has published a continuity of care self-assessment toolkit and shares actionable data and good practice with drug and alcohol partnerships on a regular basis. The toolkit is available at the following link:
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase research funding for bladder cancer.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR).
Between the 2020/21 and 2024/25 financial years, the NIHR committed £6 million for new research and programmes into bladder cancer research projects. An example of this investment includes a £2.9 million award for ‘Combination chemotherapy versus Bacillus Calmette-Guérin for high-risk non-muscle invasive bladder cancer a phase III multi-centre randomised controlled trial (COBRA)’. This study is researching whether gemcitabine and docetaxel delivered through intravesical therapy are typically recommended to patients who do not respond well to bacillus Calmette-Guerin treatment, a more common type of intravesical therapy that uses immunotherapy drugs to disrupt the processes that fuel bladder cancer growth.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including bladder cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.
Asked by: Chi Onwurah (Labour - Newcastle upon Tyne Central and West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 November 2025 to Question 83750 on Health Services: Innovation, what mechanisms are in place to monitor and evaluate the successful adoption and diffusion of health innovations across the NHS; which bodies are responsible for measuring this impact at (a) national and (b) regional levels; and how these findings inform future commissioning and policy decisions.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No organisations hold a statutory responsibility specifically to monitor or evaluate the rates of the successful adoption and spread of health innovation in the National Health Service. However, the NHS Business Services Authority, on behalf of the Office for Life Sciences, publishes the Innovation Scorecard every six months. This is of significant use to the NHS and has been published since January 2013.
The Innovation Scorecard reports on the use of medicines and medicine groupings in the NHS in England, which have been positively appraised by the National Institute for Health and Care Excellence (NICE). It reveals what NICE-recommended treatments are available at a local level within trusts and integrated care boards, as well as at national and NHS England region levels. Data limitations mean it cannot be used for performance management, but it does allow the NHS to identify variation, which, through discussion, can be explained, challenged, or acted upon.
Several organisations organise additional detailed evaluations for specific groups of health innovations. For example, the Health Innovation Network (HIN) oversees numerous national programmes which monitor the uptake and spread of selected health innovations. This helps them, and NHS England, determine how best to improve the uptake of these innovations.
Regionally, HINs also undertake monitoring and evaluation for selected innovations that they support. Integrated care boards and providers may also choose to conduct their own evaluations, using local data to understand whether innovations deliver expected improvements in outcomes or efficiency.
Asked by: Chi Onwurah (Labour - Newcastle upon Tyne Central and West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to bring forward a strategy for dental health research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR).
Whilst there are currently no plans to develop a dental health research strategy, the NIHR continues to welcome funding applications for research into any aspect of human health and care, including dental research. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Department, through the NIHR, funds clinical academic training for doctors and dentists through the Integrated Academic Training Programme. This includes Academic Clinical Fellowships (ACFs) at the pre-doctoral level and Clinical Lectureships (CLs) at the post-doctoral level. Over the last five years, 91 ACFs and 24 CLs were recruited in dentistry.
The Department also funds the NIHR Oral Health Research Incubator, which is a researcher-led initiative aimed at building dental research capacity at the national level.
Ongoing research at Newcastle University is investigating the roles and skill utilisation of professionals in dental practice.
In addition, investments in NIHR infrastructure support the country’s leading experts to develop and deliver high-quality translational, clinical, and applied research that is funded by the NIHR’s research programmes, other public funders of research, charities, and the life sciences industry. For example, through the NIHR University College London Hospitals Biomedical Research Centre’s Oral and Dental Medicine research theme.
Asked by: Jim McMahon (Labour (Co-op) - Oldham West, Chadderton and Royton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the (a) adequacy of support services for families of patients detained or likely to be detained under the Mental Health Act, and (b) benefits of developing a single point of contact service to remove the occasions where multiple calls to numerous agencies are required to secure the required support.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
While no specific assessment has been made of support services for families, we know that families play a vital role in supporting people with mental health needs through their treatment and recovery.
The Mental Health Bill includes measures that aim to ensure that people who care for the patient’s welfare, such as family or carers, are consulted by clinicians and kept informed throughout the patient’s care, treatment, and discharge.
Guidance on what information and support should be provided to families throughout the discharge process is set out in the Discharge from mental health inpatient settings statutory guidance and the Mental Health Act Code of Practice. Engagement with families, carers, and close friends should also be standard practice in community mental health services.
Integrated care boards and local authorities are also expected to work in partnership to support carers, in line with statutory guidance and local priorities. Many areas also have dedicated carers' support organisations that help connect families with resources and advocacy services, and signposting at the point of discharge from inpatient care.
Asked by: Jim McMahon (Labour (Co-op) - Oldham West, Chadderton and Royton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of advocacy voice and weight given to representations made by family members of patients over 18 years old who are detained or likely to be detained under the Mental Health Act.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
While no such specific assessment has been made, we recognise the value of representations made by family members of adult patients who are detained or likely to be detained under the Mental Health Act. That is why the Mental Health Bill, which is in its final stages, will give patients the right to appoint a nominated person to represent their interests and greater access to advocacy when they are detained.
The reforms in the bill also recognise the critical role that families and carers can play in keeping patients safe, providing insight and knowledge of their loved one’s wishes and preferences and an understanding of what keeps them safe. The bill will strengthen the rights of families and carers through changes to the nominated person role, and will require clinicians to consult with others close to the patient as they make decisions around their care where appropriate or where the patient wishes.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of recent divestments made by the life sciences industry on local economies across England, including St Neots and Mid Cambridgeshire constituency.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We do not hold specific data on the impact of recent divestments on local economies, including in St Neots and Mid Cambridgeshire, specifically.
We know this has been a challenging time for the life sciences sector, with commercial uncertainty and global competition driving recent divestment decisions. To address this, the Government has agreed a landmark trade deal with the United States which makes the United Kingdom the only country in the world to secure a zero percent tariff on pharmaceutical exports to the US, and preferential terms for medical technology exports. The Government is further securing the confidence of the pharmaceutical industry by committing to invest approximately 25% more in innovative, safe, and effective treatments, which will be the first major increase in over two decades.
We will continue to work with industry to deliver our Life Sciences Sector Plan, improve the commercial environment, and bring the benefits of a growing life sciences sector to local economies across the country.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) monitoring of the medicine supply chain and (b) verification of medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The resilience of the United Kingdom’s supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency and other colleagues across the supply chain as we progress work to co-design and deliver solutions. However, medicine shortages are a complex and global issue and everyone in the supply chain has a role to play in addressing them, as any action will require a collaborative approach.
We proactively monitor of supply and demand where there are particular concerns or threats to supply and as part of the management of live issues.
Potential disruption can also be identified early through targeted monitoring around specific events or risks. For example, growing demand and challenges in forecasting disease rates during winter, combined with broader strains on healthcare, can put extra pressure on already stressed supply chains. For the past two winters, the Department and NHS England set up a winter monitoring group to proactively monitor, analyse, and assess demand trends for a specified subset of medicines most likely to be needed. These medicines were identified by analysing historical demand data, together with known supply constraints and clinical criticality.
While manufacturers are not mandated to put verification barcodes on products, they are able to do so. This can help identify medicines accurately, automate storage and retrieval, verify expiry dates and batch numbers, and ensure the right product reaches the right patient, including automated dispensing or specific checks of the products due to be administered on hospital wards.
Asked by: Melanie Onn (Labour - Great Grimsby and Cleethorpes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that children referred for (a) neurodevelopmental and (b) paediatric assessment continue to receive care during transitions between (i) services and (ii) providers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
It is the responsibility of the integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including pre-and-post diagnostic support for children with neurodevelopmental conditions, in line with relevant National Institute for Health and Care Excellence guidelines.
The 10-Year Health Plan commits to establishing a new radical approach that will ensure that, as children and young people navigate the National Health Service, they feel comfortable and confident in managing their own health and care from 16 years old where appropriate. This will include supporting young people as they move from child to adolescent and adult services, making sure that care is developmentally appropriate throughout.
A national transition framework is being developed to help local areas set up this model or to strengthen an existing one. The principles of age-appropriate services it will set out apply to young people receiving care for the first time as well as those already on a transition pathway.
While this framework focuses on the broad principles of transition, future work will focus on specific considerations and conditions. Training is also being developed for healthcare staff to develop their skills in providing the best standards of care.
In April 2023, NHS England published a framework and guidance to deliver improved outcomes in all-age autism assessment pathways. The guidance aims to help integrated care boards and the NHS to deliver improved outcomes for children, young people, and adults referred to an autism assessment service. This includes support for them and their families/carers, while they are waiting for a diagnostic assessment and once they have received the diagnostic outcome.